How to access Lynparza from Egypt — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Egyptian patient diagnosed with BRCA-mutated advanced ovarian cancer or HER2-negative BRCA-mutated advanced breast cancer may receive a prescription for Lynparza (olaparib) from their treating medical oncologist, after germline or somatic BRCA testing confirms the mutation. Lynparza is FDA-approved in the United States across several PARP-responsive indications. In Egypt, Lynparza may not be uniformly stocked across tertiary oncology pharmacies, which is why your oncologist may be coordinating a named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor. Eligibility typically requires molecular confirmation of a BRCA1/2 mutation (or, in some indications, homologous recombination deficiency). The manufacturer is AstraZeneca (with a co-commercialisation arrangement with MSD). Dosing is typically 300 mg orally twice daily as continuous therapy. Monitoring includes complete blood count (anaemia, neutropenia, thrombocytopenia), renal function, and rare but serious myelodysplastic syndrome / acute myeloid leukaemia surveillance. Your oncologist will confirm BRCA status and sequencing against your overall treatment plan.
Is Lynparza legally importable into Egypt?
Yes — through the Egyptian Drug Authority (EDA) named-patient import framework, administered via the administering hospital's importing pharmacy and the EDA Central Administration of Pharmaceutical Affairs. Egypt has a mature named-patient mechanism that supports cross-border access to specialised oncology products.
The framework rests on four anchors: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. Applications are typically filed by the tertiary centre's importing pharmacy on the physician's behalf.
How the pathway works, step by step
- Consultation with your treating oncologist. The decision to prescribe Lynparza is clinical, based on BRCA status, tumour type, and treatment line. Your oncologist documents the rationale.
- Administering facility identification. An Egyptian tertiary oncology centre with an importing pharmacy files on behalf of the physician.
- EDA named-patient application. Your physician or the hospital's importing pharmacy files an application with EDA including clinical rationale, patient identifier, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
- Temperature-controlled shipment. Lynparza is a stable oral tablet; shipments travel with tamper-evident packaging and end-to-end documentation.
- Arrival and dispensing support. Your oncologist remains the treating clinician. Reserve Meds coordinates re-supply ahead of cycle end to avoid treatment gaps.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming BRCA status, tumour type, prior therapies, and Lynparza as the indicated treatment
- Verification of their Egyptian medical licence (MOH / Egyptian Medical Syndicate)
- A current prescription naming the product, strength, and quantity
- Patient identifier (anonymised reference preferred)
- The planned treatment cadence (continuous twice-daily therapy with monthly re-supply)
Reserve Meds provides a physician documentation kit bundling the templates EDA reviewers expect to see for oncology oral therapies under named-patient import.
Costs and timing
Lynparza's US cash-pay reference price for a 30-day supply sits in an indicative 2026 range of roughly USD 15,000–17,000. Logistics, EDA documentation handling, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first shipment arrival after cohort intake opens is approximately 14–28 days from the moment a complete EDA application is submitted. Subsequent re-supply cycles are generally faster once the pathway is established.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Lynparza specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for EDA review.
- Logistics. Temperature-stable shipment and chain-of-custody coordination.
- Concierge case lead. A named point of contact for your family and your physician throughout the process.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in Egypt? Yes, when executed through the EDA named-patient framework with appropriate documentation. The pathway has been used routinely across oncology for many years. See our trust and compliance page.
Is BRCA testing available in Egypt? Yes, several accredited labs in Egypt perform germline and somatic BRCA testing; your oncologist will confirm which lab is handling your report.
What if my oncologist has not done this before? Named-patient import is an institutional process your oncologist's hospital will have encountered. Our documentation kit closes the gap for first-time applicants.
Will private insurance cover this? Cash-pay is the default. Some Egyptian private insurers reimburse named-patient imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Lynparza coordination in Egypt.
Add me to the Lynparza waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.